Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,947,538
  • Shares Outstanding, K 59,950
  • Annual Sales, $ 1,488 M
  • Annual Income, $ 396,830 K
  • 36-Month Beta 0.98
  • Price/Sales 5.79
  • Price/Cash Flow 16.83
  • Price/Book 3.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
130.15 +14.25%
on 12/20/17
152.93 -2.77%
on 01/16/18
+15.15 (+11.34%)
since 12/19/17
3-Month
128.58 +15.65%
on 11/07/17
152.93 -2.77%
on 01/16/18
+3.70 (+2.55%)
since 10/19/17
52-Week
117.16 +26.92%
on 01/30/17
163.75 -9.19%
on 04/28/17
+24.28 (+19.51%)
since 01/19/17

Most Recent Stories

More News
Concert Pharmaceuticals Plunges on Patent Petition Setback

Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

CELG : 102.65 (+0.91%)
CNCE : 19.61 (-0.51%)
JAZZ : 148.70 (-0.37%)
VRTX : 157.97 (+0.50%)
ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632

ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.

JAZZ : 148.70 (-0.37%)
IMGN : 8.03 (+0.25%)
RHHBY : 30.6900 (+0.59%)
AMGN : 189.28 (+0.90%)
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

JAZZ : 148.70 (-0.37%)
JPM : 113.01 (-0.22%)
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder

Jazz submits a new drug application to the FDA for JZP-110 (solriamfetol) for treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

CORT : 23.98 (+1.70%)
JAZZ : 148.70 (-0.37%)
NVS : 86.94 (+0.61%)
VRX : 21.52 (-2.62%)
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing approval for solriamfetol...

JAZZ : 148.70 (-0.37%)
Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals

Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage...

JAZZ : 148.70 (-0.37%)
PFNX : 3.20 (unch)
Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on SPPI, JAZZ, ITCI, and DERM which is a click away at http://www.wallstequities.com/registration...

SPPI : 19.03 (+1.06%)
ITCI : 18.04 (+0.33%)
DERM : 28.21 (+0.82%)
JAZZ : 148.70 (-0.37%)
Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference

Jazz Pharmaceuticals plc today announced that the company will be webcasting its corporate presentation at the BMO Capital Markets Healthcare Conference in New York, NY.

JAZZ : 148.70 (-0.37%)
Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD(R), a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment of Russell...

JAZZ : 148.70 (-0.37%)
VTL : 5.50 (+2.80%)
Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Daniel N. Swisher, Jr. as president and chief operating officer, effective January 3, 2018. Mr. Swisher will report to Bruce...

JAZZ : 148.70 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 151.23
1st Resistance Point 149.96
Last Price 148.70
1st Support Level 147.47
2nd Support Level 146.25

See More

52-Week High 163.75
Last Price 148.70
Fibonacci 61.8% 145.95
Fibonacci 50% 140.46
Fibonacci 38.2% 134.96
52-Week Low 117.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.